Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quality of Life and Preference of COPD Patients After Switching From Tiotropium Monotherapy (Spiriva, Handihaler) to Dual Therapy With Tiotropium Bromide Plus Olodaterol (Spiolto, Respimat) Under Real Life Conditions in Greece (ELLACTO II Study)

X
Trial Profile

Quality of Life and Preference of COPD Patients After Switching From Tiotropium Monotherapy (Spiriva, Handihaler) to Dual Therapy With Tiotropium Bromide Plus Olodaterol (Spiolto, Respimat) Under Real Life Conditions in Greece (ELLACTO II Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms ELLACTO II Study
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Mar 2022 Status changed from active, no longer recruiting to completed.
    • 03 Dec 2021 Status changed from recruiting to active, no longer recruiting.
    • 17 Nov 2021 Planned End Date changed from 16 Feb 2022 to 2 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top